Longevity medicine under scrutiny after Greek pop star’s death

The booming longevity medicine industry is facing uncomfortable questions across Europe after the sudden death of a well-known Greek pop star who had been undergoing experimental anti-aging treatments at a private clinic.

A industry growing faster than its regulations

The singer, whose name has been widely reported in Greek media, died earlier this month at age 52. Family members say he had been receiving intravenous infusions of NAD+ boosters and high-dose vitamin cocktails, alongside peptide therapies that aren’t approved under standard medical protocols in Greece or most EU member states.

The case has rattled a sector that’s expanded dramatically in recent years. Longevity clinics have multiplied across Athens, Madrid, and Lisbon, catering to wealthy clients willing to spend anywhere from €3,000 to €20,000 per treatment cycle on therapies promising to slow cellular aging.

But almost none of it is properly regulated.

“We are seeing a proliferation of interventions marketed as cutting-edge science that haven’t passed basic clinical safety thresholds,” said a spokesperson for the European Society of Endocrinology.

Greek health authorities have opened an investigation into the clinic involved. EU health officials in Brussels are now reportedly reviewing whether existing pharmaceutical directives adequately cover these therapies. They don’t, most experts agree.

Still, the industry isn’t going anywhere. Demand is surging, the money is enormous, and the regulatory frameworks are years behind. The death of one pop star may not change that — but it’s at least forcing a conversation that’s long overdue.